<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184999</url>
  </required_header>
  <id_info>
    <org_study_id>SRCC10</org_study_id>
    <nct_id>NCT04184999</nct_id>
  </id_info>
  <brief_title>Effect of Intraoperative Dexamethasone on Post-op Dry Eye</brief_title>
  <official_title>Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SR Cornea Consultants</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SR Cornea Consultants</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the signs and symptoms of dry eye after cataract surgery between subjects&#xD;
      randomized to receive intraoperative dexamethasone in addition to the use of a standard&#xD;
      topical post-op treatment regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients requiring cataract surgery will be randomized to treatment of post-operative&#xD;
      inflammation with a single intraoperative dexamethasone injection plus a standard course of&#xD;
      topical ophthalmic corticosteroid drops or the standard treatment alone. Dry eye testing will&#xD;
      be administered at baseline, 1 week and 3 weeks following surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled prospective study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Intraoperative Use of Dexycu on Tear Film Osmolarity at 3 Weeks Postoperatively</measure>
    <time_frame>3 weeks</time_frame>
    <description>Tear Film Osmolarity as measured on Tear Lab system; validated measure of Tear Film Osmolarity Osmolarity was reported in milliosmoles per liter (mOsmol/L)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Intracameral dexamethasone 9% + postoperative topical prednisolone acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexamethasone intraocular suspension, 9% injected intracamerally at the time of cataract surgery + topical ophthalmic prednisolone acetate for 3 weeks post-operatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>postoperative topical prednisolone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical ophthalmic prednisolone acetate for 3 weeks post-operatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone intraocular suspension, 9%</intervention_name>
    <description>single dose intracameral corticosteroid</description>
    <arm_group_label>Intracameral dexamethasone 9% + postoperative topical prednisolone acetate</arm_group_label>
    <other_name>Dexycu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1% Oph Susp</intervention_name>
    <description>topical ophthalmic steroid drop</description>
    <arm_group_label>Intracameral dexamethasone 9% + postoperative topical prednisolone acetate</arm_group_label>
    <arm_group_label>postoperative topical prednisolone acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  undergoing bilateral cataract surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  central corneal staining with fluorescein and/or a tear film osmolarity of greater&#xD;
             than 340 in either eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Rao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SR Cornea Conslutants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hauser Ross Surgical Center</name>
      <address>
        <city>Sycamore</city>
        <state>Illinois</state>
        <zip>60178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <results_first_submitted>November 15, 2020</results_first_submitted>
  <results_first_submitted_qc>January 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2021</results_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>SR Cornea Consultants</investigator_affiliation>
    <investigator_full_name>Sanjay N Rao, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04184999/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT04184999/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>patients scheduled to undergo bilateral cataract surgery 40 participants were enrolled, each eye was randomized to 2 different treatment groups (intracameral dexamethasone + postoperative topical prednisolone or postoperative topical prednisolone alone)</recruitment_details>
      <pre_assignment_details>patients scheduled to undergo bilateral cataract surgery were randomly assigned to receive an intracameral injection of dexamethasone + a standard postoperative topical steroid regimen in one eye, and a standard postoperative topical steroid regimen in the other eye. Preoperative and postoperative signs of dry eye were compared between the two groups</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intracameral Dexamethasone + Postoperative Topical Prednisolone</title>
          <description>dexamethasone intraocular suspension, 9% + topical ophthalmic prednisolone&#xD;
dexamethasone intraocular suspension, 9%: single dose intracameral corticosteroid&#xD;
Prednisolone Acetate: topical ophthalmic drop for 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Postoperative Topical Prednisolone</title>
          <description>postoperative topical prednisolone for 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Week Tear Film Osmolarity Testing</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>40 participants undergoing bilateral cataract surgery were enrolled; 40 eyes were in the intracameral dexamethasone group and 40 eyes were in the standard postoperative regimen group</population>
      <group_list>
        <group group_id="B1">
          <title>Intracameral Dexamethasone + Post-operative Topical Prednisolone</title>
          <description>dexamethasone intraocular suspension, 9% + topical ophthalmic prednisolone&#xD;
dexamethasone intraocular suspension, 9%: single dose intracameral corticosteroid&#xD;
Prednisolone Acetate: topical ophthalmic drop</description>
        </group>
        <group group_id="B2">
          <title>Post-operative Topical Prednisolone</title>
          <description>topical ophthalmic prednisolone acetate&#xD;
Prednisolone Acetate: topical ophthalmic drop</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>eyes</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>40 participants were enrolled, undergoing bilateral cataract surgery 40 eyes were in the intracameral dexamethasone group 40 eyes were in the standard postoperative regimen group</description>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.49" spread="10.42"/>
                    <measurement group_id="B2" value="67.49" spread="10.42"/>
                    <measurement group_id="B3" value="67.49" spread="10.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="0"/>
                <count group_id="B2" value="0"/>
                <count group_id="B3" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>40 participants were enrolled, each eye of each participant received was assigned to a different treatment group</description>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Tear Film Osmolarity</title>
          <units>mOsmo/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="40"/>
                <count group_id="B2" value="40"/>
                <count group_id="B3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="307.475" lower_limit="292" upper_limit="320"/>
                    <measurement group_id="B2" value="307.775" lower_limit="292" upper_limit="322"/>
                    <measurement group_id="B3" value="307.625" lower_limit="292" upper_limit="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Intraoperative Use of Dexycu on Tear Film Osmolarity at 3 Weeks Postoperatively</title>
        <description>Tear Film Osmolarity as measured on Tear Lab system; validated measure of Tear Film Osmolarity Osmolarity was reported in milliosmoles per liter (mOsmol/L)</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intracameral Dexamethasone</title>
            <description>intracameral dexamethasone + postoperative prednisolone acetate for 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Postoperative Prednisolone Acetate</title>
            <description>postoperative prednisolone acetate for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Intraoperative Use of Dexycu on Tear Film Osmolarity at 3 Weeks Postoperatively</title>
          <description>Tear Film Osmolarity as measured on Tear Lab system; validated measure of Tear Film Osmolarity Osmolarity was reported in milliosmoles per liter (mOsmol/L)</description>
          <units>mOsmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.15" lower_limit="284" upper_limit="333"/>
                    <measurement group_id="O2" value="316.3" lower_limit="286" upper_limit="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.01</p_value>
            <method>ANOVA</method>
            <param_type>F-Statistic</param_type>
            <param_value>207.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intracameral Dexamethasone + Postoperative Prednisolone Acetate</title>
          <description>intracameral dexamethasone 9% injection at the time of cataract surgery + standard postoperative prednisolone acetate regimen</description>
        </group>
        <group group_id="E2">
          <title>Postoperative Prednisolone Acetate Regimen</title>
          <description>standard postoperative prednisolone acetate regimen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sanjay Rao</name_or_title>
      <organization>SR Cornea Consultants</organization>
      <phone>8476685498</phone>
      <email>sanjaynraomd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

